{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:35:11Z","timestamp":1793115311075,"version":"4.5.0"},"reference-count":154,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Genetic disease modifiers (GDMs) strongly affect disease and therapy outcomes, rendering their characterization essential for prognosis, treatment decisions, and therapy development. A paradigm for the importance of GDMs are \u03b2-hemoglobinopathies, for which a growing pipeline of emerging curative and disease-modifying therapies are based on the manipulation of GDMs. However, beyond their role as therapeutic targets, GDMs are also gaining clinical importance in the choice and planning of disease-modifying therapies, the selection and customization of curative therapies, and the equitable provision and global reach of therapies across ethnic groups and geo-economic divides. Here, we define roles of GDMs in all 4 of these fields, highlight their potential to promote choice, effectiveness, affordability, and equitable provision of treatment, and emphasize the importance of capacity building through multiethnic GDM-related research. We conclude that consideration of GDMs at all stages of development and care will be critical to addressing the needs of affected communities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018935","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:53:30Z","timestamp":1786136010000},"page":"6932-6945","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Modifying quality and equity of care: emerging roles of genetic disease modifiers in \u03b2-hemoglobinopathies"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4410-3119","authenticated-orcid":false,"given":"Panayiota L.","family":"Papasavva","sequence":"first","affiliation":[{"name":"1Blood Disorder Genetics & Thalassemia, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atinuke M.","family":"Dosunmu-Ogunbi","sequence":"additional","affiliation":[{"name":"2Dana-Farber\/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oni O.","family":"Morohuntodun","sequence":"additional","affiliation":[{"name":"2Dana-Farber\/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2681-4355","authenticated-orcid":false,"given":"Petros","family":"Kountouris","sequence":"additional","affiliation":[{"name":"1Blood Disorder Genetics & Thalassemia, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4801-6250","authenticated-orcid":false,"given":"Julie","family":"Makani","sequence":"additional","affiliation":[{"name":"3Muhimbili Sickle Cell Program, Department of Hematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania"},{"name":"4Centre for Haematology, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin Alwi","family":"Zilfalil","sequence":"additional","affiliation":[{"name":"5Malaysian Node of the Human Variome Project, School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia"},{"name":"6Human Genome Centre, School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2643-765X","authenticated-orcid":false,"given":"Baba P. D.","family":"Inusa","sequence":"additional","affiliation":[{"name":"7Faculty of Life Sciences and Medicine, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha M.","family":"Archer","sequence":"additional","affiliation":[{"name":"2Dana-Farber\/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3920-9584","authenticated-orcid":false,"given":"Carsten W.","family":"Lederer","sequence":"additional","affiliation":[{"name":"1Blood Disorder Genetics & Thalassemia, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafsah","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musa","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliyu Dahiru","family":"Waziri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Biemond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Fijnvandraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soteroula","family":"Christou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiana","family":"Makariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Katsantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morohuntodu","family":"Oni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manika","family":"Kreka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Glenth\u00f8j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kleanthous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Kountouris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten W","family":"Lederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriaki","family":"Michailidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiota","family":"Papasavva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Phylactides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralea","family":"StephaNu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjon","family":"Cnossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Rijneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjaak","family":"Philipsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hovhannisyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedele","family":"Bonifazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Giannuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Kerkhoffs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Ropero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livingstone Gayus","family":"Dogara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeliki","family":"Balassopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dimopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Diamantidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Pyrovolaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Mohseny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Ootjers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis L","family":"Harteveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hadjigavriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonieta","family":"Lukangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Tshilolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja Zahratul","family":"Azma Raja Sabudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chilota Chibufe","family":"Efobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Brons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Schols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mas Rina","family":"Wati Abdul Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seow","family":"ChiN Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Labarque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Makelburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martje","family":"Stein-Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Suijker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"van Beers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obiageli","family":"Nnodu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Felice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella Ellena","family":"Ronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Lettre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilfalil Bin","family":"Alwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Badikyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"issue":"2","key":"2026102711120824200_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ajhg.2017.06.004","article-title":"From peas to disease: modifier genes, network resilience, and the genetics of health","volume":"101","author":"Riordan","year":"2017","journal-title":"Am J Hum Genet"},{"issue":"16","key":"2026102711120824200_bib2","doi-asserted-by":"crossref","first-page":"8928","DOI":"10.3390\/ijms25168928","article-title":"Loss-of-function variants in SUPT5H as modifying factors in beta-thalassemia","volume":"25","author":"Harteveld","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026102711120824200_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-4939-7299-9_2","article-title":"Genetic basis and genetic modifiers of \u03b2-thalassemia and sickle cell disease","volume":"1013","author":"Thein","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"2026102711120824200_bib6","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3390\/ijms27041890","article-title":"Special issue \u201cgenetic modifiers of hemoglobinopathies: recent advances and future directions\u201d","volume":"27","author":"Lederer","year":"2026","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2026102711120824200_bib12","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.3390\/ijms25084263","article-title":"Pharmacogenomics of drugs used in \u03b2-thalassemia and sickle-cell disease: from basic research to clinical applications","volume":"25","author":"Gambari","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2026102711120824200_bib14","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.3390\/ijms25105427","article-title":"Systematic review of genetic modifiers associated with the development and\/or progression of nephropathy in patients with sickle cell disease","volume":"25","author":"Labarque","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2026102711120824200_bib23","doi-asserted-by":"crossref","first-page":"e2337484","DOI":"10.1001\/jamanetworkopen.2023.37484","article-title":"Genetic variation and sickle cell disease severity: a systematic review and meta-analysis","volume":"6","author":"Kirkham","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2026102711120824200_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.hoc.2022.12.001","article-title":"Molecular basis and genetic modifiers of thalassemia","volume":"37","author":"Tesio","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"issue":"22","key":"2026102711120824200_bib25","doi-asserted-by":"crossref","first-page":"11886","DOI":"10.3390\/ijms252211886","article-title":"Genetic modifiers of hemoglobin expression from a clinical perspective in hemoglobinopathy patients with beta thalassemia and sickle cell disease","volume":"25","author":"Diamantidis","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2026102711120824200_bib21","doi-asserted-by":"crossref","first-page":"E416","DOI":"10.1002\/ajh.26323","article-title":"The International Hemoglobinopathy Research Network (INHERENT): an international initiative to study the role of genetic modifiers in hemoglobinopathies","volume":"96","author":"Kountouris","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"2026102711120824200_bib26","doi-asserted-by":"crossref","first-page":"100098","DOI":"10.1016\/j.bglo.2026.100098","article-title":"Pilot of the International Hemoglobinopathy Research Network (INHERENT) for a multi-ethnic genome-wide association study","volume":"2","author":"Kountouris","year":"2026","journal-title":"Blood Glob Hematol"},{"key":"2026102711120824200_bib27","doi-asserted-by":"publisher","DOI":"10.1101\/209361","article-title":"ITHANET: information and database community portal for haemoglobinopathies","author":"Kountouris","year":"31  2017","journal-title":"bioRxiv"},{"key":"2026102711120824200_bib28","doi-asserted-by":"crossref","first-page":"101185","DOI":"10.1016\/j.blre.2024.101185","article-title":"Revolutionising healing: gene editing\u2019s breakthrough against sickle cell disease","volume":"65","author":"Dimitrievska","year":"2024","journal-title":"Blood Rev"},{"issue":"5","key":"2026102711120824200_bib7","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1073\/pnas.0711566105","article-title":"Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia","volume":"105","author":"Uda","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2026102711120824200_bib4","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.3390\/ijms25063400","article-title":"Impact of \u03b1-globin gene expression and \u03b1-globin modifiers on the phenotype of \u03b2-thalassemia and other hemoglobinopathies: implications for patient management","volume":"25","author":"Traeger-Synodinos","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"17","key":"2026102711120824200_bib5","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood-2017-10-811505","article-title":"Induction of fetal hemoglobin synthesis by CRISPR\/Cas9-mediated editing of the human \u03b2-globin locus","volume":"131","author":"Antoniani","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2026102711120824200_bib8","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1016\/j.ymthe.2022.05.002","article-title":"Development of a double shmiR lentivirus effectively targeting both BCL11A and ZNF410 for enhanced induction of fetal hemoglobin to treat \u03b2-hemoglobinopathies","volume":"30","author":"Liu","year":"2022","journal-title":"Mol Ther"},{"issue":"6","key":"2026102711120824200_bib9","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2002-02-0387","article-title":"X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction","volume":"100","author":"Yu","year":"2002","journal-title":"Blood"},{"issue":"6","key":"2026102711120824200_bib10","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/ijlh.14130","article-title":"First reported co-occurrence of \u201cGATA1-mutated X-linked thrombocytopenia with thalassemia (XLTT)\u201d with heterozygous \u03b2-thalassemia","volume":"45","author":"Singh","year":"2023","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"2026102711120824200_bib11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/ijlh.14431","article-title":"Novel mutations in SUPT5H gene associated with beta-thalassemia phenotype","volume":"47","author":"Agarwal","year":"2025","journal-title":"Int J Lab Hematol"},{"issue":"6","key":"2026102711120824200_bib13","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/sj.tpj.6500433","article-title":"Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea","volume":"7","author":"Ma","year":"2007","journal-title":"Pharmacogenomics J"},{"issue":"9","key":"2026102711120824200_bib15","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.3390\/ijms26094456","article-title":"Genetic modifiers associated with vaso-occlusive crises and acute pain phenomena in sickle cell disease: a scoping review","volume":"26","author":"Sophocleous","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2026102711120824200_bib16","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood.V92.9.3455","article-title":"Apolipoprotein E \u03b54 allele as a genetic risk factor for left ventricular failure in homozygous \u03b2-thalassemia","volume":"92","author":"Economou-Petersen","year":"1998","journal-title":"Blood"},{"issue":"1","key":"2026102711120824200_bib17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/10245332.2018.1502397","article-title":"Association of GSTT1\/GSTM1 and ApoE variants with left ventricular diastolic dysfunction in thalassaemia major patients","volume":"24","author":"Singh","year":"2019","journal-title":"Hematology"},{"issue":"12","key":"2026102711120824200_bib18","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.3390\/ijms25126317","article-title":"Genetic modifiers of stroke in patients with sickle cell disease-a scoping review","volume":"25","author":"Oni","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"22","key":"2026102711120824200_bib19","doi-asserted-by":"crossref","first-page":"16263","DOI":"10.3390\/ijms242216263","article-title":"Endocrinopathies in hemoglobinopathies: what is the role of iron?","volume":"24","author":"Evangelidis","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2026102711120824200_bib20","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.3390\/ijms25094792","article-title":"Pulmonary hypertension in sickle cell disease: novel findings of gene polymorphisms related to pathophysiology","volume":"25","author":"Chatzidavid","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2026102711120824200_bib22","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/s41467-025-57413-5","article-title":"FLT1 and other candidate fetal haemoglobin modifying loci in sickle cell disease in African ancestries","volume":"16","author":"Wonkam","year":"2025","journal-title":"Nat Commun"},{"issue":"3","key":"2026102711120824200_bib29","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s11033-021-06977-8","article-title":"Revisiting fetal hemoglobin inducers in beta-hemoglobinopathies: a review of natural products, conventional and combinatorial therapies","volume":"49","author":"Mukherjee","year":"2022","journal-title":"Mol Biol Rep"},{"issue":"14","key":"2026102711120824200_bib30","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1073\/pnas.79.14.4428","article-title":"5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons","volume":"79","author":"DeSimone","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9105","key":"2026102711120824200_bib31","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0140-6736(05)78941-8","article-title":"US FDA approves first drug for sickle-cell anaemia","volume":"351","author":"Ault","year":"1998","journal-title":"The Lancet"},{"issue":"11","key":"2026102711120824200_bib32","doi-asserted-by":"crossref","first-page":"e0307049","DOI":"10.1371\/journal.pone.0307049","article-title":"Identification of small molecule agonists of fetal hemoglobin expression for the treatment of sickle cell disease","volume":"19","author":"Yang","year":"2024","journal-title":"PLoS One"},{"issue":"suppl 1","key":"2026102711120824200_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00277-005-0008-x","article-title":"Decitabine: a historical review of the development of an epigenetic drug","volume":"84","author":"de Vos","year":"2005","journal-title":"Ann Hematol"},{"issue":"suppl 1","key":"2026102711120824200_bib34","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/blood-2025-1157","article-title":"Pociredir, a novel oral once-daily fetal hemoglobin inducer: results from the phase 1b pioneer study in adult participants with severe sickle cell disease and hydroxyurea intolerance or unresponsiveness","volume":"146","author":"Alan","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026102711120824200_bib35","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2025-612","article-title":"Pomalidomide downregulates FIZ1 to induce fetal hemoglobin in adult erythroid progenitors","volume":"146","author":"Serra","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026102711120824200_bib36","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/bloodadvances.2020002725","article-title":"The use of luspatercept for thalassemia in adults","volume":"5","author":"Cappellini","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2026102711120824200_bib37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3324\/haematol.2018.198887","article-title":"Sotatercept, a novel transforming growth factor \u03b2 ligand trap, improves anemia in \u03b2-thalassemia: a phase II, open-label, dose-finding study","volume":"104","author":"Cappellini","year":"2019","journal-title":"Haematologica"},{"issue":"10498","key":"2026102711120824200_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0140-6736(25)00635-X","article-title":"Mitapivat in adults with non-transfusion-dependent \u03b1-thalassaemia or \u03b2-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial","volume":"406","author":"Taher","year":"2025","journal-title":"Lancet"},{"issue":"16","key":"2026102711120824200_bib39","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1182\/bloodadvances.2023012467","article-title":"Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease","volume":"8","author":"Saraf","year":"2024","journal-title":"Blood Adv"},{"key":"2026102711120824200_bib40","volume-title":"U.S. FDA Approves Agios\u2019 AQVESMETM (Mitapivat) for the Treatment of Anemia in Adults With Alpha- or Beta-Thalassemia","year":"2025"},{"key":"2026102711120824200_bib41","volume-title":"Agios\u2019 PYRUKYND\u00ae (Mitapivat) Approved in the European Union for Adults With Thalassemia","year":"2026"},{"issue":"1","key":"2026102711120824200_bib42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41467-022-35404-0","article-title":"A specific G9a inhibitor unveils BGLT3 lncRNA as a universal mediator of chemically induced fetal globin gene expression","volume":"14","author":"Takase","year":"2023","journal-title":"Nat Commun"},{"issue":"21","key":"2026102711120824200_bib43","doi-asserted-by":"crossref","first-page":"11408","DOI":"10.3390\/ijms252111408","article-title":"Genetic polymorphisms associated with fetal hemoglobin (HbF) levels and F-cell numbers: a systematic review of genome-wide association studies","volume":"25","author":"Stephanou","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"suppl 1","key":"2026102711120824200_bib44","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1182\/blood-2023-179331","article-title":"Targeted degradation of the WIZ transcription factor for gamma globin de-repression","volume":"142","author":"Ting","year":"2023","journal-title":"Blood"},{"issue":"10468","key":"2026102711120824200_bib45","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/S0140-6736(24)01884-1","article-title":"Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype \u03b2-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial","volume":"404","author":"Kwiatkowski","year":"2024","journal-title":"Lancet"},{"issue":"9","key":"2026102711120824200_bib46","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1097\/MS9.0000000000002409","article-title":"FDA approval of Casgevy and Lyfgenia: a dual breakthrough in gene therapies for sickle cell disease","volume":"86","author":"Rahmat","year":"2024","journal-title":"Ann Med Surg"},{"issue":"12","key":"2026102711120824200_bib47","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41551-024-01222-6","article-title":"Enhancement of erythropoietic output by Cas9-mediated insertion of a natural variant in haematopoietic stem and progenitor cells","volume":"8","author":"Luna","year":"2024","journal-title":"Nat Biomed Eng"},{"issue":"11","key":"2026102711120824200_bib48","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/bloodadvances.2016002303","article-title":"KLF1 directly activates expression of the novel fetal globin repressor ZBTB7A\/LRF in erythroid cells","volume":"1","author":"Norton","year":"2017","journal-title":"Blood Adv"},{"issue":"8","key":"2026102711120824200_bib49","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1182\/blood.2023022190","article-title":"Elevating fetal hemoglobin: recently discovered regulators and mechanisms","volume":"144","author":"Khandros","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026102711120824200_bib50","first-page":"e40","article-title":"Rpl13a snoRNAs U34 and U35a: new targets for sickle cell disease complications","volume":"137","author":"Chauhan","year":"2025","journal-title":"Circ Res"},{"issue":"10","key":"2026102711120824200_bib51","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3390\/medicina57101106","article-title":"The role of miRNAs as therapeutic tools in sickle cell disease","volume":"57","author":"Cyrus","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"2026102711120824200_bib52","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease","volume":"384","author":"Esrick","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"2026102711120824200_bib53","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"2026102711120824200_bib54","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1182\/bloodadvances.2024013932","article-title":"UM171 enhances fitness and engraftment of gene-modified hematopoietic stem cells from patients with sickle cell disease","volume":"8","author":"Liu","year":"2024","journal-title":"Blood Adv"},{"key":"2026102711120824200_bib55","unstructured":"CorrectSequence Therapeutics Co, Ltd\n          . A single-arm, open-label phase I clinical trial to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamic profile of a single dose of CS-101 injection in subjects with \u03b2-thalassemia major. ClinicalTrials.gov identifier: NCT06291961. Updated 10 February 2024. Accessed 1 August 2026. https:\/\/clinicaltrials.gov\/study\/NCT06291961."},{"key":"2026102711120824200_bib56","unstructured":"Beam Therapeutics Inc\n          . BEACON: a atudy evaluating the safety and efficacy of BEAM-101 in patients with severe sickle cell disease (BEACON). Clinicaltrials.gov. 2024. Accessed 1 August 2026. https:\/\/clinicaltrials.gov\/study\/NCT05456880."},{"issue":"1","key":"2026102711120824200_bib57","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12033-025-01368-x","article-title":"CRISPR\/Cas9 system as a promising therapy in thalassemia and sickle cell disease: a systematic review of clinical trials","volume":"68","author":"Ahmed","year":"2026","journal-title":"Mol Biotechnol"},{"key":"2026102711120824200_bib58","author":"Beaney","year":"2025"},{"issue":"11","key":"2026102711120824200_bib59","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1182\/bloodadvances.2024015574","article-title":"BCL11A-deficient human erythropoiesis is impaired in vitro and after xenotransplantation into mice","volume":"9","author":"Jang","year":"2025","journal-title":"Blood Adv"},{"issue":"11","key":"2026102711120824200_bib60","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1038\/s41596-023-00877-w","article-title":"Design and application of the transformer base editor in mammalian cells and mice","volume":"18","author":"Han","year":"2023","journal-title":"Nat Protoc"},{"key":"2026102711120824200_bib61","doi-asserted-by":"publisher","DOI":"10.1101\/2025.01.13.632780","article-title":"A prime editing strategy to rewrite the \u03b3-globin promoters and reactivate fetal hemoglobin for sickle cell disease","author":"Chalumeau","year":"14  2025","journal-title":"bioRxiv"},{"key":"2026102711120824200_bib62","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/bs.mie.2025.01.010","article-title":"CRISPRoff epigenome editing for programmable gene silencing in human cell lines and primary T cells","volume":"712","author":"Pattali","year":"2025","journal-title":"Methods Enzymol"},{"issue":"3","key":"2026102711120824200_bib63","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41551-025-01480-y","article-title":"In vivo genome editing of human haematopoietic stem cells for treatment of blood disorders using mRNA delivery","volume":"10","author":"Xu","year":"2026","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"2026102711120824200_bib64","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1038\/s41467-023-41153-5","article-title":"Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model","volume":"14","author":"Uchida","year":"2023","journal-title":"Nat Commun"},{"issue":"9","key":"2026102711120824200_bib65","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41591-025-03817-1","article-title":"Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial","volume":"31","author":"Agarwal","year":"2025","journal-title":"Nat Med"},{"issue":"6","key":"2026102711120824200_bib66","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41587-023-01915-4","article-title":"Genotoxic effects of base and prime editing in human hematopoietic stem cells","volume":"42","author":"Fiumara","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"13","key":"2026102711120824200_bib67","doi-asserted-by":"crossref","first-page":"gkaf637","DOI":"10.1093\/nar\/gkaf637","article-title":"Dissecting the epigenetic regulation of the fetal hemoglobin genes to unravel a novel therapeutic approach for \u03b2-hemoglobinopathies","volume":"53","author":"Amistadi","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2026102711120824200_bib68","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13059-026-03974-7","article-title":"Functional correction and genome integrity with duplex base editing of \u03b2-thalassemic hematopoietic stem cells","volume":"27","author":"Papaioannou","year":"2026","journal-title":"Genome Biol"},{"key":"2026102711120824200_bib69","doi-asserted-by":"crossref","first-page":"1175794","DOI":"10.3389\/fonc.2023.1175794","article-title":"Long-term health outcomes of allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Kelkar","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"2026102711120824200_bib70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/bloodadvances.2024014104","article-title":"Gene therapy in transfusion-dependent non-\u03b20\/\u03b20 genotype \u03b2-thalassemia: first real-world experience of beti-cel","volume":"9","author":"Mirza","year":"2025","journal-title":"Blood Adv"},{"issue":"6","key":"2026102711120824200_bib71","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41397-018-0045-1","article-title":"Hydroxyurea in the management of sickle cell disease: pharmacogenomics and enzymatic metabolism","volume":"18","author":"Yahou\u00e9d\u00e9hou","year":"2018","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"2026102711120824200_bib72","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41397-025-00372-3","article-title":"Exploring pharmacogenetic factors influencing hydroxyurea response in tanzanian sickle cell disease patients: a genomic medicine approach","volume":"25","author":"Nkya","year":"2025","journal-title":"Pharmacogenomics J"},{"key":"2026102711120824200_bib73","doi-asserted-by":"crossref","first-page":"101","DOI":"10.12688\/gatesopenres.16370.1","article-title":"CYP2D6 pharmacogenetics in Nigerian sickle cell disease: Phase 1 of Implementing Pharmacogenomics Testing for Effective Care and Treatment in Africa (iPROTECTA) program","volume":"9","author":"Adeagbo","year":"2025","journal-title":"Gates Open Res"},{"issue":"9","key":"2026102711120824200_bib74","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1097\/j.pain.0000000000002910","article-title":"A systematic review of genome-wide association studies for pain, nociception, neuropathy, and pain treatment responses","volume":"164","author":"Li","year":"2023","journal-title":"Pain"},{"issue":"9","key":"2026102711120824200_bib75","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.neurol.2020.01.356","article-title":"Epidemiology of neurological diseases in older adults","volume":"176","author":"Dumurgier","year":"2020","journal-title":"Rev Neurol (Paris)"},{"issue":"3S","key":"2026102711120824200_bib76","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.annemergmed.2020.08.009","article-title":"Trends in sickle cell disease\u2013related mortality in the United States, 1979 to 2017","volume":"76","author":"Payne","year":"2020","journal-title":"Ann Emerg Med"},{"issue":"15","key":"2026102711120824200_bib77","doi-asserted-by":"crossref","first-page":"e15417","DOI":"10.14814\/phy2.15417","article-title":"Modulation of blood pressure regulatory genes in the Agtrap-Plod1 locus associated with a deletion in Clcn6","volume":"10","author":"Klemens","year":"2022","journal-title":"Physiol Rep"},{"issue":"4","key":"2026102711120824200_bib78","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1002\/ctm2.152","article-title":"Genetic modifiers of long-term survival in sickle cell anemia","volume":"10","author":"Wonkam","year":"2020","journal-title":"Clin Transl Med"},{"issue":"1","key":"2026102711120824200_bib79","first-page":"4","article-title":"Differences in the clinical and genotypic presentation of sickle cell disease around the world","volume":"15","author":"Saraf","year":"2014","journal-title":"Paediatr Respir Rev"},{"issue":"24","key":"2026102711120824200_bib80","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/blood.2024027839","article-title":"Diabetes mellitus and APOL1 genotype increase the risk for chronic kidney disease progression in sickle cell disease","volume":"145","author":"Sun","year":"2025","journal-title":"Blood"},{"issue":"23","key":"2026102711120824200_bib81","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1182\/bloodadvances.2019000916","article-title":"American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease","volume":"3","author":"Liem","year":"2019","journal-title":"Blood Adv"},{"issue":"10","key":"2026102711120824200_bib82","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3324\/haematol.2015.124875","article-title":"Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy","volume":"100","author":"Saraf","year":"2015","journal-title":"Haematologica"},{"issue":"2","key":"2026102711120824200_bib83","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.htct.2020.01.009","article-title":"Polymorphisms in the heme oxygenase-1 and bone morphogenetic protein receptor type 1b genes and estimated glomerular filtration rate in Brazilian sickle cell anemia patients","volume":"43","author":"Chinedu","year":"2021","journal-title":"Hematol Transfus Cell Ther"},{"issue":"3","key":"2026102711120824200_bib84","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.20800","article-title":"Estimated glomerular filtration rate in sickle cell anemia is associated with polymorphisms of bone morphogenetic protein receptor 1B","volume":"82","author":"Nolan","year":"2007","journal-title":"Am J Hematol"},{"issue":"3","key":"2026102711120824200_bib85","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2141.2011.08832.x","article-title":"MYH9 and APOL1 are both associated with sickle cell disease nephropathy","volume":"155","author":"Ashley-Koch","year":"2011","journal-title":"Br J Haematol"},{"issue":"8","key":"2026102711120824200_bib86","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41581-023-00721-0","article-title":"Inaxaplin for the treatment of APOL1-associated kidney disease","volume":"19","author":"Gbadegesin","year":"2023","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"2026102711120824200_bib87","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1681\/ASN.0000000804","article-title":"Management of kidney disease with sickle cell disease","volume":"36","author":"Abbasi","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2026102711120824200_bib88","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1182\/bloodadvances.2021004232","article-title":"Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease","volume":"5","author":"Leonard","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2026102711120824200_bib89","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0213-9626(08)70046-5","article-title":"Hematopoietic stem cell homing: the long, winding and adhesive road to the bone marrow","volume":"27","author":"Hidalgo","year":"2008","journal-title":"Inmunolog\u00eda"},{"issue":"2","key":"2026102711120824200_bib90","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/curroncol31020044","article-title":"Homing and engraftment of hematopoietic stem cells following transplantation: a pre-clinical perspective","volume":"31","author":"Hasan","year":"2024","journal-title":"Curr Oncol"},{"issue":"8","key":"2026102711120824200_bib91","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/s41588-022-01121-z","article-title":"Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis","volume":"54","author":"Kar","year":"2022","journal-title":"Nat Genet"},{"issue":"1","key":"2026102711120824200_bib92","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5045\/br.2018.53.1.61","article-title":"Expression of adhesion molecules on CD34+ cells from steady-state bone marrow before and after mobilization and their association with the yield of CD34+ cells","volume":"53","author":"Cecyn","year":"2018","journal-title":"Blood Res"},{"issue":"3","key":"2026102711120824200_bib93","doi-asserted-by":"crossref","first-page":"e0228878","DOI":"10.1371\/journal.pone.0228878","article-title":"Analysis of a large single institution cohort of related donors fails to detect a relation between SDF1\/CXCR4 or VCAM\/VLA4 genetic polymorphisms and the level of hematopoietic progenitor cell mobilization in response to G-CSF","volume":"15","author":"Garciaz","year":"2020","journal-title":"PLoS One"},{"issue":"9","key":"2026102711120824200_bib94","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3390\/pharmaceutics11090440","article-title":"Impact of GSTA1 polymorphisms on busulfan oral clearance in adult patients undergoing hematopoietic stem cell transplantation","volume":"11","author":"Michaud","year":"2019","journal-title":"Pharmaceutics"},{"issue":"4","key":"2026102711120824200_bib95","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/FTD.0000000000000180","article-title":"Glutathione transferase gene variants influence busulfan pharmacokinetics and outcome after myeloablative conditioning","volume":"37","author":"Bremer","year":"2015","journal-title":"Ther Drug Monit"},{"issue":"7","key":"2026102711120824200_bib96","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/s41409-021-01233-w","article-title":"Hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation for thalassemia major: incidence, management, and outcome","volume":"56","author":"Lai","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"2026102711120824200_bib97","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.bbmt.2019.11.026","article-title":"Genetic susceptibility to hepatic sinusoidal obstruction syndrome in pediatric patients undergoing hematopoietic stem cell transplantation","volume":"26","author":"Ansari","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"2026102711120824200_bib98","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1158\/1541-7786.MCR-08-0519","article-title":"Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites","volume":"7","author":"McNeill","year":"2009","journal-title":"Mol Cancer Res"},{"issue":"1","key":"2026102711120824200_bib99","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41409-022-01828-x","article-title":"Clinically relevant germline variants in allogeneic hematopoietic stem cell transplant recipients","volume":"58","author":"Lahtinen","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"1-2","key":"2026102711120824200_bib100","first-page":"275","article-title":"Human DNA repair genes, 2005","volume":"577","author":"Wood","year":"2005","journal-title":"Mutat Res"},{"issue":"1","key":"2026102711120824200_bib101","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/bmt.2017.214","article-title":"Secondary solid cancer following hematopoietic cell transplantation in patients with thalassemia major","volume":"53","author":"Santarone","year":"2018","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2026102711120824200_bib102","doi-asserted-by":"crossref","first-page":"e30738","DOI":"10.1002\/pbc.30738","article-title":"Busulfan and subsequent malignancy: an evidence-based risk assessment","volume":"71","author":"Long-Boyle","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2026102711120824200_bib103","doi-asserted-by":"crossref","first-page":"2522967","DOI":"10.1080\/07853890.2025.2522967","article-title":"Risk of cancer in patients with thalassemia and sickle cell disease: a systematic review","volume":"57","author":"Merolle","year":"2025","journal-title":"Ann Med"},{"issue":"3","key":"2026102711120824200_bib104","first-page":"255","article-title":"Donor-derived malignancy and transplantation morbidity: risks of patient and donor genetics in allogeneic hematopoietic stem cell transplantation","volume":"30","author":"Williams","year":"2024","journal-title":"Transpl Cell Ther"},{"key":"2026102711120824200_bib105","doi-asserted-by":"crossref","first-page":"e01236","DOI":"10.7554\/eLife.01236","article-title":"Global cellular response to chemotherapy-induced apoptosis","volume":"2","author":"Wiita","year":"2013","journal-title":"eLife"},{"issue":"25","key":"2026102711120824200_bib106","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1182\/blood.2024024636","article-title":"cMPL-based purification and depletion of human hematopoietic stem cells: implications for pretransplant conditioning","volume":"145","author":"Araki","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026102711120824200_bib107","doi-asserted-by":"crossref","first-page":"101808","DOI":"10.1016\/j.gendis.2025.101808","article-title":"In vivo gene therapy: a strategy for mutations, degenerations, and tumors","volume":"13","author":"Wang","year":"2026","journal-title":"Genes Dis"},{"issue":"9","key":"2026102711120824200_bib108","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.3390\/ijms26094067","article-title":"Fine-tuning homology-directed repair (HDR) for precision genome editing: current strategies and future directions","volume":"26","author":"Haider","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2026102711120824200_bib109","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1038\/s41467-023-38448-y","article-title":"Hematopoietic reconstitution dynamics of mobilized- and bone marrow-derived human hematopoietic stem cells after gene therapy","volume":"14","author":"Scala","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"2026102711120824200_bib110","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41551-024-01310-7","article-title":"Hormonally mediated mechanical remodelling of human haematopoietic stem cells enhances their bone-marrow engraftment","volume":"9","year":"2025","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"2026102711120824200_bib111","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/16078454.2020.1852762","article-title":"Association of cytotoxic T-lymphocyte antigen-4 (CTLA-4) single nucleotide polymorphism in donors with clinical outcome after allogeneic hematopoietic stem cell transplantation: a meta-analysis","volume":"26","author":"Wang","year":"2021","journal-title":"Hematology"},{"issue":"14","key":"2026102711120824200_bib112","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/bloodadvances.2020001927","article-title":"Recipient and donor genetic variants associated with mortality after allogeneic hematopoietic cell transplantation","volume":"4","author":"Martin","year":"2020","journal-title":"Blood Adv"},{"key":"2026102711120824200_bib113","doi-asserted-by":"crossref","first-page":"1100306","DOI":"10.3389\/fimmu.2023.1100306","article-title":"Biomarkers for early complications post hematopoietic cell transplantation: insights and challenges","volume":"14","author":"Balakrishnan","year":"2023","journal-title":"Front Immunol"},{"issue":"suppl 3","key":"2026102711120824200_bib114","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ajh.27594","article-title":"Prediction and prognostication of acute graft-versus-host disease by MAGIC biomarkers","volume":"100","author":"Levine","year":"2025","journal-title":"Am J Hematol"},{"issue":"1","key":"2026102711120824200_bib115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood-2015-03-636753","article-title":"Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment","volume":"126","author":"McDonald","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2026102711120824200_bib116","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1182\/blood.2021011121","article-title":"Clonal hematopoiesis in sickle cell disease","volume":"138","author":"Pincez","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2026102711120824200_bib117","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2025-8","article-title":"Sickle cell disease is associated with early-onset clonal hematopoiesis involving DNA damage response pathway mutations","volume":"146","author":"Weeks","year":"2025","journal-title":"Blood"},{"issue":"13","key":"2026102711120824200_bib118","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1182\/blood.2025030898","article-title":"Increased prevalence of clonal hematopoiesis in children with sickle cell disease","volume":"147","author":"Ulloa","year":"2026","journal-title":"Blood"},{"issue":"4","key":"2026102711120824200_bib119","doi-asserted-by":"crossref","first-page":"e156060","DOI":"10.1172\/JCI156060","article-title":"Clonal hematopoiesis in sickle cell disease","volume":"132","author":"Liggett","year":"2022","journal-title":"J Clin Invest"},{"issue":"suppl 1","key":"2026102711120824200_bib120","doi-asserted-by":"crossref","first-page":"8213","DOI":"10.1182\/blood-2022-159246","article-title":"High incidence of clonal hematopoiesis in transfusion-dependent thalassemia patients","volume":"140","author":"Solomou","year":"2022","journal-title":"Blood"},{"issue":"7831","key":"2026102711120824200_bib121","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"issue":"13","key":"2026102711120824200_bib122","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2017-05-783233","article-title":"Increased risk of leukemia among sickle cell disease patients in California","volume":"130","author":"Brunson","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2026102711120824200_bib123","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.3390\/jcm11113160","article-title":"Clonal hematopoiesis and the risk of hematologic malignancies after curative therapies for sickle cell disease","volume":"11","author":"Gondek","year":"2022","journal-title":"J Clin Med"},{"issue":"6","key":"2026102711120824200_bib124","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1182\/blood-2017-04-777029","article-title":"DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions","volume":"130","author":"Buscarlet","year":"2017","journal-title":"Blood"},{"issue":"26","key":"2026102711120824200_bib125","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"2026102711120824200_bib126","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"2026102711120824200_bib127","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1182\/bloodadvances.2025016053","article-title":"An ethical allocation scheme for scarce gene therapies in sickle cell disease and transfusion-dependent \u03b2-thalassemia","volume":"9","author":"Kelkar","year":"2025","journal-title":"Blood Adv"},{"issue":"17","key":"2026102711120824200_bib128","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1182\/bloodadvances.2025016943","article-title":"Reality bites: allocating gene therapy for hemoglobinopathies","volume":"9","author":"Tubman","year":"2025","journal-title":"Blood Adv"},{"issue":"24","key":"2026102711120824200_bib129","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1182\/blood-2015-03-633594","article-title":"\u03b1-Globin as a molecular target in the treatment of \u03b2-thalassemia","volume":"125","author":"Mettananda","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2026102711120824200_bib130","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood.V50.2.303.303","article-title":"X-linked syndrome of platelet dysfunction, thrombocytopenia, and imbalanced globin chain synthesis with hemolysis","volume":"50","author":"Thompson","year":"1977","journal-title":"Blood"},{"key":"2026102711120824200_bib131","volume-title":"LYFGENIA. Package insert","year":"2023"},{"issue":"7","key":"2026102711120824200_bib132","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.3324\/haematol.2021.278952","article-title":"Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea","volume":"107","author":"Allard","year":"2022","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2026102711120824200_bib133","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood-2019-128320","article-title":"Selecting \u00df-thalassemia patients for gene therapy: a decision-making algorithm","volume":"134","author":"Baronciani","year":"2019","journal-title":"Blood"},{"issue":"17","key":"2026102711120824200_bib134","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood.2020010020","article-title":"Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo","volume":"138","author":"Psatha","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2026102711120824200_bib135","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1016\/j.ymthe.2025.03.018","article-title":"CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery","volume":"33","author":"Papp","year":"2025","journal-title":"Mol Ther"},{"issue":"1","key":"2026102711120824200_bib141","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41746-026-02553-1","article-title":"Regulating complexity in AI-enabled omics and multi-omics technologies for precision medicine","volume":"9","author":"Welzel","year":"2026","journal-title":"Npj Digit Med"},{"issue":"8","key":"2026102711120824200_bib136","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/15578100251359276","article-title":"Clinical and genetic predictors of sickle cell nephropathy: a global systematic review","volume":"29","author":"Banda","year":"2025","journal-title":"OMICS: A J Integr Biol"},{"issue":"5","key":"2026102711120824200_bib137","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1586\/17474086.2015.1078235","article-title":"A systematic review of known mechanisms of hydroxyurea-induced foetal haemoglobin for treatment of sickle cell disease","volume":"8","author":"Pule","year":"2015","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"2026102711120824200_bib138","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41588-022-01257-y","article-title":"Human genetic diversity alters off-target outcomes of therapeutic gene editing","volume":"55","author":"Cancellieri","year":"2023","journal-title":"Nat Genet"},{"issue":"1","key":"2026102711120824200_bib139","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajhg.2017.05.012","article-title":"A genetic variant ameliorates \u03b2-thalassemia severity by epigenetic-mediated elevation of human fetal hemoglobin expression","volume":"101","author":"Chen","year":"2017","journal-title":"Am J Hum Genet"},{"key":"2026102711120824200_bib140","doi-asserted-by":"crossref","first-page":"201071","DOI":"10.1016\/j.humgen.2022.201071","article-title":"Genetic bases and modifiers of \u03b2-thalassemia in Argentina","volume":"33","author":"Scheps","year":"2022","journal-title":"Hum Gene"},{"issue":"3-4","key":"2026102711120824200_bib142","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41434-021-00284-4","article-title":"Towards access for all: 1st working group report for the Global Gene Therapy Initiative (GGTI)","volume":"30","author":"Adair","year":"2023","journal-title":"Gene Ther"},{"issue":"4","key":"2026102711120824200_bib143","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s43441-025-00769-z","article-title":"Beyond reimbursement status: availability of advanced therapy medicinal products across the European Union","volume":"59","author":"\u010cechov\u00e1","year":"2025","journal-title":"Ther Innov Regul Sci"},{"key":"2026102711120824200_bib144","doi-asserted-by":"crossref","first-page":"105713","DOI":"10.1016\/j.ebiom.2025.105713","article-title":"Access to gene therapy for sickle cell disease in Africa","volume":"115","author":"Makani","year":"2025","journal-title":"eBioMedicine"},{"issue":"12","key":"2026102711120824200_bib145","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ajh.26754","article-title":"Blood diseases in Africa: redressing unjust disparities is an urgent unmet need","volume":"97","author":"Makani","year":"2022","journal-title":"Am J Hematol"},{"issue":"database issue","key":"2026102711120824200_bib146","doi-asserted-by":"crossref","first-page":"D975","DOI":"10.1093\/nar\/gkt1211","article-title":"NCBI\u2019s database of genotypes and phenotypes: dbGaP","volume":"42","author":"Tryka","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2026102711120824200_bib147","volume-title":"Data Versioning Release Notes","year":"2024"},{"issue":"4","key":"2026102711120824200_bib148","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3390\/jpm12040552","article-title":"Global Globin Network Consensus paper: classification and stratified roadmaps for improved thalassaemia care and prevention in 32 countries","volume":"12","author":"Halim-Fikri","year":"2022","journal-title":"J Pers Med"},{"issue":"12","key":"2026102711120824200_bib149","doi-asserted-by":"crossref","first-page":"e70258","DOI":"10.1002\/hem3.70258","article-title":"HELIOS action: advancing research, education, and equity in hemoglobinopathies across Europe and beyond","volume":"9","author":"Chatzimatthaiou","year":"2025","journal-title":"Hemasphere"},{"key":"2026102711120824200_bib150","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1017\/gheg.2016.17","article-title":"H3Africa AWI-Gen Collaborative Centre: a resource to study the interplay between genomic and environmental risk factors for cardiometabolic diseases in four sub-Saharan African countries","volume":"1","author":"Ramsay","year":"2016","journal-title":"Glob Health Epidemiol Genom"},{"issue":"1","key":"2026102711120824200_bib151","doi-asserted-by":"crossref","first-page":"1846904","DOI":"10.1080\/16549716.2020.1846904","article-title":"Strengthening research capacity in LMICs to address the global NCD burden","volume":"13","author":"Malekzadeh","year":"2020","journal-title":"Glob Health Action"},{"key":"2026102711120824200_bib152","author":"Ramakrishnan","year":"2025"},{"key":"2026102711120824200_bib153","unstructured":"African Research and Innovative Initiative for Sickle Cell Education: Improving Research Capacity for Service Improvement. ARISE Initiative. 2020. Accessed 9 March 2026. https:\/\/www.ariseinitiative.org\/."},{"issue":"2865","key":"2026102711120824200_bib154","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1126\/science.110.2865.543","article-title":"Sickle cell anemia a molecular disease","volume":"110","author":"Pauling","year":"1949","journal-title":"Science (New York, NY)"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/6932\/2595062\/blooda_adv-2025-018935-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/6932\/2595062\/blooda_adv-2025-018935-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:12:29Z","timestamp":1793113949000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/20\/6932\/570083\/Modifying-quality-and-equity-of-care-emerging"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":154,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026,10,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018935","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,27]]},"published":{"date-parts":[[2026,10,14]]}}}